

DOCKET NO.: RTS-0250

#3 / K.T.  
10/31  
F.D.S.  
"Express Mail" Label No.: EL918916891US  
Date of Deposit: 9/14/2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Brett P. Monia et al.

Serial No.: Not yet assigned      Group No.: Not yet assigned

Filed: herewith

For: **Antisense Modulation of fibroblast growth factor receptor 2  
Expression**

BOX SEQUENCE

Assistant Commissioner for Patents  
Washington DC 20231

INFORMATION DISCLOSURE STATEMENT


Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above identified application, no additional fee is required.

Copies of each of the references listed on the attached Form PTO-1449 are enclosed.

Date: Sept. 14, 2001

Respectfully submitted,

  
Laurel Spear Bernstein  
Registration No. 37,280

ISIS PHARMACEUTICALS, INC.  
Carlsbad Research Center  
2292 Faraday Avenue  
Carlsbad, CA 92008